CD22 Positive
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (NCT03851081) | Roswell Park Cancer Institute | 2021-01-21 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038) | M.D. Anderson Cancer Center | 2019-05-15 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03698552) | M.D. Anderson Cancer Center | 2018-08-24 |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (NCT03094611) | M.D. Anderson Cancer Center | 2017-11-30 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML (NCT02311998) | M.D. Anderson Cancer Center | 2015-04-16 |
Track CD22 Positive automatically
Every clearance here is in the API, with alerts when new ones post.